Remdesivir Criteria Save on Costs Without Affecting Outcomes

Originally published by our sister publication Infectious Disease Special EditionBy Ethan CoveyA systemwide shift to more restrictive remdesivir (Veklury, Gilead Sciences) eligibility criteria led to a substantial reduction in drug use and associated costs—without worsening clinical outcomes—according to a retrospective analysis presented at the ASHP Midyear 2025 Clinical Meeting & Exhibition, in Las Vegas.figure img { width:100% !important; } figcaption { padding: 5px; backgroun